Hypertension

Programs

Sort by

Page

Showing 1 - 9 of 9 documents.

Hypertension

Oct 1, 2008 13:15 EDT

Data on ARBs continue to impress. Stay informed on the implications of late-breaking trial data from the 2008 ESC meeting with interviews conducted by Dr Weber with Drs Pfeffer, McMurray, Swedberg, and Agabati-Rosei.

Hypertension

Is Aggressive Blood Pressure Lowering Needed in Stage I Hypertension?

Sep 30, 2008 10:16 EDT

Join Drs Weber and Izzo as they take a hard look at stage I hypertensive patients and answer the question: Is lower better?

Hypertension

First response: Improving outcomes - is it all about blood pressure?

1 COMMENT - Jul 25, 2008 11:00 EDT

First hand reports from the joint meeting in Berlin of European Society of Hypertension/ International Society of Hypertension

Hypertension

The weight of evidence mounts for ARBs

8 COMMENTS - Jun 30, 2008 16:20 EDT

New trials and more data suggest a more established role for ARBs

Hypertension

RAAS inhibition: The foundation for combination therapy

11 COMMENTS - Jun 27, 2008 09:31 EDT

Using combination therapy to achieve better control rates: Does new data from outcome trials suggest a new paradigm?

Hypertension

A focus on nitric oxide

19 COMMENTS - May 30, 2008 11:16 EDT

Hypertension, hypercholesterolemia, insulin resistance, atherosclerosis, coronary heart disease, heart failure: are they all at the mercy of nitric oxide? Join Drs Weber, Cohn, Mason and Cockcroft in a discussion on the role nitric oxide plays in vascular health.

Hypertension

Managing hypertension Combination therapy: The new first line?

Dec 19, 2007 15:40 EST

Clinicians are exploring a new and compelling role for combination therapy in hard-to-treat hypertension in patients with type 2 diabetes.

Hypertension

The Cardiorenal Connection Role of Microalbuminuria (MAU) in Cardiovascular Risk Stratification

2 COMMENTS - Dec 19, 2007 15:35 EST

The assessment of microalbuminuria (MAU) is an important prognostic indicator for CVD and renal damage and should be an element in an overall cardiometabolic fitness approach.

Hypertension

A SMARTer approach to renal disease

Nov 27, 2007 17:00 EST

Angiotensin receptor blockers, primarily known as safe and effective antihypertensive agents, are not generally recognized as having a dramatic dose response effect — on blood pressure, that is. But these agents do more than lower BP. New data from SMART (SupraMaximal Doses of Atacand and Renal Therapy) show surprising effects on proteinuria.

Previews

View all CME programs >>

Inside: Hypertension

Hypertension

First response: Improving outcomes - is it all about blood pressure?

1 COMMENT - Jul 25, 2008 11:00 EDT

First hand reports from the joint meeting in Berlin of European Society of Hypertension/ International Society of Hypertension

Hypertension

The weight of evidence mounts for ARBs

8 COMMENTS - Jun 30, 2008 16:20 EDT

New trials and more data suggest a more established role for ARBs

Hypertension

A First Response: ARBs on Center Stage

Oct 1, 2008 13:15 EDT

Hypertension

Is Aggressive Blood Pressure Lowering Needed in Stage I Hypertension?

Sep 30, 2008 10:16 EDT

Join Drs Weber and Izzo as they take a hard look at stage I hypertensive patients and answer the question: Is lower better?

Hypertension

A focus on nitric oxide

19 COMMENTS - May 30, 2008 11:16 EDT

Hypertension

Managing hypertension Combination therapy: The new first line?

Dec 19, 2007 15:40 EST

Clinicians are exploring a new and compelling role for combination therapy in hard-to-treat hypertension in patients with type 2 diabetes.

Hypertension

The Cardiorenal Connection Role of Microalbuminuria (MAU) in Cardiovascular Risk Stratification

2 COMMENTS - Dec 19, 2007 15:35 EST

The assessment of microalbuminuria (MAU) is an important prognostic indicator for CVD and renal damage and should be an element in an overall cardiometabolic fitness approach.

We comply with the HONcode standard
for trustworthy health information: verify here.

	Occasionally
	No, never
	No, because I don't have access to this technology
	Yes, routinely